Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength. A significant unmet need exists for treatment that is more effective than current therapies and well tolerated, thereby improving patient compliance. We assess how current therapies are differentiated based on the performance of key drug attributes and measure their impact on rheumatologists’ and endocrinologists’ prescribing behavior. We also evaluate the most important unmet needs in the treatment of osteoporosis and discuss the impact of the launch of Evenity on these needs. Our conjoint analysis reveals the trade-offs in key attributes, such as risk of fracture, safety, dosing burden, and price, that surveyed physicians are willing to make when considering new treatment options for osteoporosis.


  • What are the treatment drivers and goals for osteoporosis?
  •  What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do U.S. and European physicians rate the performances of current therapies, including Eli Lilly’s Forteo, Amgen / UCB’s Evenity, Amgen’s Prolia, and Radius Health’s Tymlos, on key treatment drivers and goals?
  • How has the launch of Evenity in the United States affected the need for more-efficacious osteoporosis treatments?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new osteoporosis drug?


Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European rheumatologists and endocrinologists fielded in March 2020

Key companies: Eli Lilly, Amgen, Radius Health, Merck, Novartis

Key drugs: Evenity, Prolia, Forteo, Tymlos

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Executive Summary
      • Unmet Need - Osteoporosis - Executive Summary - May 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Osteoporosis
      • Key Findings: Unmet Need in Osteoporosis and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Osteoporosis Market and Emerging Therapy Insights
        • Opportunity: Focus on Developing Drugs with Enhanced Efficacy
        • Opportunity: Availability of Therapies That Are Cost-Effective with Convenient Dosing Regimens to Improve Compliance Rates
        • Opportunity: Therapies with an Improved Safety and Tolerability Profile to Address Patients' Reluctance and Improve Drug Acceptance
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Osteoporosis Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Market Scenario
    • Appendix
      • Bibliography

Author(s): Shambhavi Shukla, MTech

Shambhavi Shukla, MTech ., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Disorders team at Decision Resources Group. Before joining DRG, Shambhavi was with Evalueserve for four years, where she worked closely with top pharmaceutical companies, assisting with commercial and technical ad-hoc requests. During her tenure, she delivered competitive landscape and market insight projects for various indications, including schizophrenia, multiple sclerosis, and myopia. She holds a master’s degree in biotechnology from Amity University, India.

Related Reports

Osteoporosis | Landscape & Forecast | Disease Landscape & Forecast

With an increasing prevalence, due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches wil...

View Details

Osteoporosis | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of osteoporosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We repo...

View Details

Osteoporosis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key osteoporosis patient p...

View Details

Osteoporosis | Epidemiology | Americas

DRG Epidemiology’s coverage of osteoporosis comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceut...

View Details